echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Genxi Bio will announce the preclinical results of CD19/CD7 dual-targeting allogeneic CAR-T candidate product GC502 in ASH2021

    Genxi Bio will announce the preclinical results of CD19/CD7 dual-targeting allogeneic CAR-T candidate product GC502 in ASH2021

    • Last Update: 2021-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recent popular reports from Yimaike ★ Dr.
    Sersch, Chief Medical Officer of Genxi Bio: Innovation never stops, only to unlock the shackles of lifeFengke Creative ★ Genxi Bio and Mingji Bio have reached a cooperation and will target CLDN18.
    2 positive entities New Immune Cell Therapy for Tumor Development November 5, 2021/MedClub News/--Suzhou, Shanghai, China and Palo Alto, California, U.
    S.
    Recently, Genxi Biotechnology Group (NASDAQ: GRCL) ; Referred to as "Genxi Bio"), a global clinical-stage biopharmaceutical company dedicated to the development of efficient and economical cell therapy for cancer treatment, today announced that it will be in the form of an electronic poster during the 63rd American Society of Hematology (ASH) annual meeting Announced the preclinical research data of its allogeneic chimeric antigen receptor (CAR) T cell therapy candidate product GC502 for the treatment of B cell malignancies
    .

    The detailed report will be presented in the "Cellular Immunotherapy: Basic Research and Translational Medicine" session at 5:30-7:30 pm (Eastern Time) on December 11, 2021
    .

    GC502 is a CD19/CD7 dual-targeted, ready-to-use allogeneic CAR-T cell monotherapy developed based on Genxi's proprietary TruUCAR technology platform for the treatment of B-cell malignancies
    .

    The innovative dual-targeting CAR design is designed to specifically target malignant tumor cells to CD19 CAR on cellular drugs, while CD7 CAR is used to inhibit host versus graft rejection (HvG)
    .

    This unique design gives GC502 the potential to become a monotherapy
    .

    The pre-clinical results show that: GC502 has significant anti-tumor activity in vivo, and has a good inhibitory effect on HvG without the need for additional immunosuppressive treatments.

    .

     TruUCAR is a proprietary technology platform created by Genxi Bio to develop a series of high-quality allogeneic CAR-T cell therapies
    .

    The platform can use T cells from healthy donors who do not need human leukocyte antigen (HLA) matching to produce "ready-to-use" products on a large scale at a lower cost
    .

     Dr.
    Xinxin Wang, Vice President of Genxi Biology Research and Development Department, said: “The encouraging preclinical research data of GC502 fully verified the good efficacy of our dual-targeted CAR-T products based on the TruUCAR platform and the flexibility to apply to new targets.
    It further indicates that Genxi Bio’s proprietary ready-to-use, allogeneic single-agent CAR-T therapy is expected to be applied to a wider group of cancer patients in the future
    .

    " Senior Vice President, R&D Director of Genxi Biosciences Dr.
    Shen Lianjun added: “GC502 not only exhibits excellent anti-tumor activity in preclinical studies, but also has a good inhibitory effect on host versus graft rejection
    .

    These research results make us look forward to the early promotion of GC502 candidate products.
    Enter the clinical research stage and continue to expand the company's early research and development pipeline, and continue to explore more safe, effective, and highly accessible new immune cell therapies for relapsed and refractory hematological tumors to benefit patients around the world
    .

    "The details of the electronic poster report are as follows.
    : Summary of the 63rd ASH Annual Conference and Exhibition in 2021 148500: Summary of preclinical research results of allogeneic ready-to-use CD19/CD7 dual-targeted CAR-T cell therapy (GC502) for the treatment of B-cell malignancies Release time: 2021 9:00 am, November 4, 2015.
    The name of the report session: Cellular Immunotherapy: Basic Research and Translational Medicine Poster Presentation Time: 5:30-7:30 pm, December 11, 2021 About GC502GC502 is a CD19/ developed based on the TruUCAR platform CD7 dual-targeted ready-to-use allogeneic CAR-T therapy candidate product
    .

    At present, the candidate product is in the exploratory preclinical research stage, mainly for the treatment of B-cell malignancies, including: acute B-lymphocytic leukemia (B-ALL) and acute non-Hodgkin’s lymphoma (B-NHL)
    .

    GC502 is prepared using T cells from healthy donors who do not require human leukocyte antigen (HLA) matching
    .

    In addition, in the design of this product, Genxi Biotech also embeds an enhanced molecule into the basic structure of TruUCAR to enhance the expansion capacity of TruUCAR T cells
    .

    Thanks to the dual CAR design that targets CD19/CD7 at the same time and the optimization in terms of in vivo durability, GC502 has demonstrated excellent anti-tumor activity in preclinical research models, as well as resistance to host versus graft (HvG) rejection.
    Suppressing effect
    .

     About acute B-lymphocytic leukemia (B-ALL) and acute non-Hodgkin’s lymphoma (B-NHL) Acute lymphocytic leukemia (ALL) is a malignant hematological tumor characterized by the abnormal proliferation of immature lymphocytes in the bone marrow.
    Usually includes acute T-lymphocytic leukemia (T-ALL) or acute B-lymphocytic leukemia (B-ALL)
    .

    About 64,000 patients are diagnosed with ALL each year worldwide; in 2020, approximately 6,000 and 7,400 patients are expected to be diagnosed with ALL in the United States and China, respectively, of which B-ALL patients account for approximately 85%-88% of all ALL patients1
    .

    Non-Hodgkin’s Lymphoma (NHL) is a type of hematological malignancy that originates in lymph nodes and other lymphoid tissues, and is commonly found in B cells (B-NHL)
    .

    Approximately 510,000 patients are diagnosed with NHL each year in the world; in 2020, more than 77,000 and 68,000 patients are expected to be diagnosed with NHL in the United States and China, respectively, of which B-NHL patients account for approximately 85% of the total number of NHL patients 2
    .

     About TruUCART RuUCAR is a technology platform of Genxi Biotech with intellectual property rights.
    It aims to develop high-quality "ready-to-use" allogeneic CAR-T cell therapy, further reducing costs and providing better convenience
    .

    TruUCAR achieves differentiated design through gene editing, which can control host-versus-graft rejection (HvG) and graft-versus-host disease (GvHD) separately without the need for combination with immunosuppressive drugs
    .

    TruUCAR's innovative dual CAR design enables CAR targeting tumor antigens to kill tumor cells, while CAR targeting CD7 inhibits host-to-graft response, enabling TruUCAR T cells to become a single-drug "ready-to-use" allogeneic CAR-T therapy
    .

     About Genxi Biotech Genxi Biotechnology Group (referred to as "Genxi Bio") is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapies
    .

    Utilizing its pioneering FasTCAR and TruUCAR technology platforms, Genxi Bio is developing a number of autologous and allogeneic rich clinical-stage cancer treatment product pipelines
    .

    These products are expected to overcome the major industry challenges that continue to exist in traditional CAR-T therapy, including long production time, poor production quality, high treatment costs, and lack of effective treatment options for solid tumors
    .

    To learn more about GracellBio, please visit LinkedIn account @GracellBio
    .

    Cautionary Statement Regarding Forward-Looking Statements The statements in this press release regarding future expectations, plans, prospects, and other non-historical facts may include those defined under the Private Securities Litigation Reform Act of 1995 "Forward-looking Statement"
    .

    These statements include, but are not limited to, statements related to the expected transaction and completion time of this issuance
    .

    These statements may but not necessarily contain the following vocabulary and the corresponding negative or similar vocabulary: purpose, expectation, belief, estimation, prediction, prediction, plan, possibility, prospect, plan, potential, speculation, drafting, seeking, possible , Should, will
    .

    Due to various important factors, actual results may differ materially from forward-looking statements, and there is no guarantee that any forward-looking statements will be realized
    .

    These important factors include the factors mentioned in the "Risk Factors" section of Form 20-F of the annual report by Genxi Biotech, as well as the potential risks, uncertainties and other important factors in the subsequent submission of Genxi Biotech to the SEC.
    Discussion of factors
    .

    Any forward-looking statements in this statement only reflect current expectations, and Genxi Biotech is not responsible for publicly updating or reviewing any forward-looking statements, whether based on new information, future events or other reasons
    .

    Readers are requested not to rely on forward-looking statements after the publication date of this press release
    .

    References: 1.
    Data source:Clarivate | DRG:Acute Lymphoblastic Leukemia-Epidemiology 2.
    Data source:Clarivate | DRG:Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia-Epidemiology
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.